Skip to main content
Springer logoLink to Springer
letter
. 2019 Feb 12;98(4):1041–1043. doi: 10.1007/s00277-019-03612-2

A case report of congenital erythropoietic anemia II in China with a novel mutation

Hong Zhang 1, Wuqing Wan 1,, Xiaoyan Liu 1, Chuan Wen 1, Ying Liu 1, Senlin Luo 1, Xiao Sun 1, Shizhe Liu 1
PMCID: PMC6423316  PMID: 30747246

Dear Editor,

Congenital erythropoietic anemias (CDAs) are a group of rare inherited diseases [1]. So far, the CDAs are mainly divided into four types (type I to type IV), and the CDA type II is the most common type. It is caused by a mutation in the SEC23B gene. To date, 67 causative mutations in the SEC23B gene have been described [25] (the complete mutational spectrum of SEC23B is shown in Table 1).

Table 1.

Mutational spectrum of SEC23B

Exon Nucleotide change AA change
Missense mutations
 2 c.40C > T R14W
 2 c.53G > A R18H
 2 c.74C > A P25H
 2 c.197G > A C66Y
 4 c.325G > A E109K
 5 c.494G > A G165D
 7 c.716A > G D239G
 8 c.938G > A R313H
 8 c.953T > C I318T
 9 c.1043A > C D348A
 10 c.1157A > G Q386R
 11 c.1254T > G I418M
 11 c.1307C > T S436L
 11 c.1352G > T C451F
 12 c.1385A > G Y462C
 12 c.1445A > G Q482R
 13 c.1453A > G T485A
 13 c.1467C > G H489Q
 13 c.1489C > T R497C
 13 c.1508G > A R503Q
 14 c.1571C > T A524V
 14 c.1588C > T R530W
 14 c.1589G > A R530Q
 14 c.1654C > T L552F
 15 c.1685A > G Y562C
 15 c.1727T > C F576S
 15 c.1733T > C L578P
 15 c.1735T > A Y579N
 16 c.1808C > T S603L
 16 c.1832G > C R611P
 16 c.1858A > G M620V
 16 c.1859T > C M620T
 17 c.1910T > G V637G
 17 c.1949T > C L650S
 17 c.1968T > G F656L
 18 c.2101C > T R701C
 17 c.2108C > T P703L
 18 c.2129C > T T710M
 19 c.2166A > C K723Q
 19 c.2180C > T S727F
 20 c.2270A > C H757P
Nonsense mutations
 2 c.71G > A W24X
 3 c.235C > T R79X
 5 c.367C > T R123X
 5 c.568C > T R190X
 6 c.640C > T Q214X
 6 c.649C > T R217X
 7 c.790C > T R264X
 8 c.970C > T R324X
 9 c.1015C > T R339X
 10 c.1201C > T R401X
 14 c.1603C > T R535X
 14 c.1648C > T R550X
 14 c.1660C < T R554X
Splicing mutations
 2–3 c.221 + 31A > G
 3–4 c.279 + 3A > G
 6 c.689 + 1G > A
 9–10 c.1109 + 1G > A
 9–10 c.1109 + 5G > A
 18–19 c.2149-2A > G
Frameshift mutations
 3 c.222-817_366 + 4242del
 5 c.387(delG)
 5 c.428_428delAinsCG
 9 c.1063(delG)
 16 c.1821delT
 17 c.1962-64(delT)
 19 c.2150(delC)
Small deletion
 16 c.1857_1859delCAT

We report a patient with typical clinical manifestations and laboratory findings, a 6-year-old girl who had suffered jaundice at the age of 6 months with low hemoglobin levels at 80 g/L. Her hemoglobin concentration fluctuated between 80 and 100 g/L, and the severe hemoglobin lows were complicated with jaundice, which was not treated. There was no clear diagnosis even after comprehensive examinations. She tended to catch colds easily. Her parents and a younger brother were all healthy. Upon physical examination, the proband displayed anemic facies and yellowish discoloration of the mucous membrane and skin. Abdominal examination showed hepatomegaly and splenomegaly.

Laboratory investigations showed a hemoglobin level of 78 g/L. Reticulocyte count was 0.069 × 10^12/L, and reticulocyte ratio was 3.16%. Total bilirubin was 53.9 μmol/L (normal, 0–21), of which 42.7 μmol/L was indirect (normal, 0–19). G6PD deficiency was not found. Red blood cell folate and hemoglobin electrophoresis gave results within normal limits. Serum vitamin B12 was 736 pmol/L (normal, 133–675). Serum iron, ferritin, and transferrin were all within normal limits. Erythrocyte osmotic fragility test was normal. Acidified glycerol hemolysis test and Coombs test were negative. Light microscope observation of a bone marrow smear revealed hyperplasia and binucleated late erythroblasts (Fig. 1a).

Fig. 1.

Fig. 1

a A binucleated late erythroblast on bone marrow smear. b Heterozygous mutation (c.T1859C) of the proband and her father. c Heterozygous mutation (c. C1571T) of the proband and her mother

Genetic testing of the proband, her little brother, and her parents performed at Shanghai Xin Peijing Medical Laboratory showed two heterozygous changes in the SEC23B gene of chromosome 20, which were heterozygote c.C1571T: p.A524V (on exon 14) and heterozygote c.T1859C: p.M620T (on exon 16). The proband was a compound heterozygote with mutation c.C1571T from her mother and c.T1859C from her father. Her little brother inherited the mutation from their mother (Fig. 1b, c).

In this case, sequencing analysis of CDA-related genes revealed that there were two mutations of SEC23B gene in this family: c. C1571T: p.A524V (on exon 14) and c.T1859C: p.M620T (on exon 16). The proband was a compound heterozygote with mutation c.C1571T from her mother and c.T1859C from her father. Since she was the only patient in this family, the illness of the proband was inferred to have been caused by a compound heterozygous mutation and not by a single mutation. The mutation c. C1571T has been reported [2]. A search of PubMed indicated that the mutation c.T1859C has not yet been reported. Here, we attempted to prove that it was a causative mutation. First, this mutation is located in the gelsolin domain of SEC23B protein, which has an extremely important function. The sequences around this domain are highly conserved among multiple species shown using the Protein BLAST tool. We used the PolyPhen tool to evaluate the possible effects of this mutation. The result was “probably damaging.” Russo [4] reported a CDA II patient whose gene mutation was c.A1858G (on exon 16), adjacent to the mutation site of the proband. Both these mutations resulted in a change in the amino acid at position 620. We believe that mutation c.T1859C is a causative and novel mutation of CDA II.

Electronic supplementary material

ESM 1 (2.1MB, rar)

(RAR 2181 kb)

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Lolascon A, D’Agostaro G, Perrotta S, et al. Congenital dyserythropoietic anemia type II: molecular basis and clinical aspects.[J] Haematologica. 1996;81(6):543. [PubMed] [Google Scholar]
  • 2.Lolascon A, Esposito MR, Russo R. Clinical aspects and pathogenesis of congenital dyserythropoietic anemias: from morphology to molecular approach.[J] Haematologica. 2012;97(12):1786–1794. doi: 10.3324/haematol.2012.072207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lolascon A, Russo R, Esposito MR, et al. Molecular analysis of 42 patients with congenital dyserythropoietic anemia type II: new mutations in the SEC23B gene and a search for a genotype-phenotype relationship.[J] Haematologica. 2010;95(5):708–715. doi: 10.3324/haematol.2009.014985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Russo R, Esposito MR, Asci R, Gambale A, Perrotta S, Ramenghi U, Forni GL, Uygun V, Delaunay J, Iolascon A. Mutational spectrum in congenital dyserythropoietic anemia type II: identification of 19 novel variants in SEC23B gene.[J] Am J Hematol. 2010;85(12):915–920. doi: 10.1002/ajh.21866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wang Y, Ru Y, Liu G, et al. Identification of CDAN1, C15ORF41 and SEC23B mutations in Chinese patients affected by congenital dyserythropoietic anemia.[J] Gene. 2017;640:73. doi: 10.1016/j.gene.2017.10.027. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ESM 1 (2.1MB, rar)

(RAR 2181 kb)


Articles from Annals of Hematology are provided here courtesy of Springer

RESOURCES